^
    Back
    Association details:
    Biomarker:RARS1-MAD1L1 fusion
    Cancer:Nasopharyngeal Carcinoma
    Drug:cisplatin (DNA synthesis inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    Clin Cancer Res
    Title:

    The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma

    Excerpt:
    The vector-harboring CNE2 cell-based xenografts displayed a greater response to DDP than the RARS-MAD1L1-expressing cell-based xenografts (Figures 3J and 3K). These results suggest that RARS-MAD1L1 induced chemoresistance in cancer cells.
    DOI:
    10.1158/1078-0432.CCR-17-0352